Kairos Biotech Ltd Secures €1 Million Follow‑On Investment to Advance Antibody and T‑Cell Receptor Engineering for Diagnostics and Therapeutics
St. Asaph, UK — 24 February 2026
Kairos Biotech Ltd today announced the closing of a €1 million follow‑on investment from Dutch investment vehicle Myosotis Investments B.V., which will now hold 46.1% of the company’s fully diluted equity.
Kairos Biotech’s leadership team comprises founder and CEO Dr Mike Bunce, R&D Director Ben Passey, Senior Scientist David Pye, and Investor Director Dr Wietse Mulder. The company operates from the Wrexham University OpTIC Technology Centre in St Asaph, North Wales.
The transaction was completed with legal support from Herke van Hulst and Angela Saldanha of Osborne Clarke (Amsterdam) and Catherine Williams of Keystone Law (London).
Accelerating Innovation in Transplant Immunology
The new investment will accelerate Kairos Biotech’s nanoscale engineering programmes focused on antibodies and T‑cell receptors. These engineered molecules are being developed to enable next‑generation transplant diagnostics and targeted immunotherapeutic applications.
Transplant Need & Kairos Biotech's Approach
Successful kidney and solid‑organ transplantation relies on avoiding harmful immune rejection. However, many patients harbour pre‑formed anti‑donor T‑ and B‑cell responses, which significantly limit suitable donor matches. As a result, some patients may face years‑long waits for a viable transplant opportunity.
Kairos Biotech is developing proprietary small molecules that can both enhance diagnostic precision and modulate — or potentially eliminate — deleterious anti‑donor immune responses. Early research indicates that these nano‑engineered molecules can specifically interfere with and remove targeted immunological barriers, offering the possibility of inducing durable, donor‑specific transplant tolerance.
Such an approach has the potential to reduce transplant waiting times for high‑risk patients, broaden donor compatibility, and improve long‑term graft survival.
About Kairos Biotech Ltd
Kairos Biotech is an early‑stage biotechnology company founded by experienced biotech entrepreneurs. The company focuses on the discovery and engineering of proprietary small molecules for application in diagnostics and immunotherapy, with an initial emphasis on improving transplantation outcomes by overcoming immune‑based barriers.
About Myosotis Investments B.V.
Founded in 2024, Myosotis Investments is the private holding company of Wietse Mulder, PhD. Myosotis invests in innovative life science companies, with a particular focus on molecular diagnostics and technologies reshaping the future of healthcare.
Media Contacts
Kairos Biotech Ltd
Dr Mike Bunce, CEO
Email: Info@KairosBiotech.com
Website: www.KairosBiotech.com
Telephone: +44 7549 823564
Myosotis Investments B.V.
Dr Wietse Mulder, Managing Partner
Email: info@myosotisinvestments.com
Website: https://myosotisinvestments.com
Telephone: +31 6 5126 5864
